A Phase 3 clinical trial (NCT05586802) investigating semaglutide for metabolic and reproductive health in men with Klinefelter Syndrome reached its primary completion on April 1, 2026. The study aims to evaluate the effects of modulating sex steroid balance on metabolic health and spermatogenesis in this population.

Background

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, widely known for its use in type 2 diabetes and chronic weight management. In this trial, it is being investigated within the context of Klinefelter Syndrome (KFS), a genetic condition affecting males, characterized by the presence of an extra X chromosome. Men with KFS often experience metabolic health issues and reproductive challenges, including hypogonadism and impaired spermatogenesis. The study explores whether modulating sex steroid balance, potentially through interventions like semaglutide for weight loss, can improve these outcomes.

Trial design

The study, titled "Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome" (NCT05586802), is a Phase 3 trial. It has an estimated enrollment of 150 participants diagnosed with Klinefelter Syndrome. The trial investigates multiple interventions, including semaglutide, anastrozole, human chorionic gonadotropin, and testosterone gel, to assess their impact on metabolic and reproductive health.

What this means

The primary completion of this Phase 3 trial signifies a key milestone in the study of interventions for Klinefelter Syndrome. While specific results are not yet available, the completion indicates that the main data collection period for the primary objectives has concluded. Future data releases will provide insights into the efficacy of semaglutide and other interventions in addressing metabolic and reproductive health challenges in men with KFS.

Source

Information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05586802, titled "Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome," was recorded on April 1, 2026 on clinicaltrials.gov.